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Introduction
Mature resting B lymphocytes capture antigen (Ag) via their 
specifi  c B cell receptor (BCR), which corresponds to a surface 
Ig coupled to a signaling module formed by the Igα/Igβ dimer 
(Cambier et al., 1994; Reth and Wienands, 1997). In addition to 
Ag internalization, BCR stimulation triggers a complex cascade 
of signaling events that ultimately leads to the activation of 
B lymphocytes, which can then initiate the development of ger-
minal centers. To complete germinal center formation, activated 
lymphocytes must process and present internalized Ag onto 
  major histocompatibility complex (MHC) class II molecules to 
primed CD4 T cells, a process referred to as T-B cooperation 
(McHeyzer-Williams et al., 2000; Mitchison, 2004). It was re-
cently shown that upon immunization, Ag-specifi  c B lympho-
cytes are among the fi  rst lymphoid organ cells to acquire Ag and 
express the corresponding surface MHC–peptide complexes, 
highlighting the capacity of B cells to effi  ciently process and 
present BCR-internalized Ag onto MHC class II molecules in 
vivo (Byersdorfer et al., 2004; Catron et al., 2004).
MHC class II molecules assemble shortly after synthesis 
in the ER with a type II transmembrane protein, the invariant 
chain (Ii), which prevents their premature association with 
endogenous peptides (Wolf and Ploegh, 1995). In addition, Ii 
contains in its cytoplasmic tail the targeting signals that deliver 
MHC class II molecules into endocytic compartments for them 
to be loaded with antigenic peptides (Nakagawa and Rudensky, 
1999; Villadangos et al., 1999; Watts, 2001). Such peptides 
  result from the degradation of internalized Ag by endocytic 
  proteases, which must also cleave Ii to free MHC II molec-
ules for loading, a reaction catalyzed by the chaperone H2-DM 
(Nakagawa and Rudensky, 1999; Villadangos et al., 1999; 
Watts, 2001).
Therefore, successful Ag presentation relies on its effi  -
cient targeting into endocytic compartments competent for 
  processing (i.e., wherein it concentrates together with MHC 
class II, proteases, and H2-DM molecules). This corresponds to an 
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A
ntigen (Ag) capture and presentation onto ma-
jor histocompatibility complex (MHC) class II 
molecules by B lymphocytes is mediated by their 
surface Ag receptor (B cell receptor [BCR]). Therefore, 
the transport of vesicles that carry MHC class II and 
BCR–Ag complexes must be coordinated for them to 
converge for processing. In this study, we identify the 
  actin-associated motor protein myosin II as being es-
sential for this process. Myosin II is activated upon BCR 
  engagement and associates with MHC class II–invariant 
chain complexes. Myosin II inhibition or depletion com-
promises the convergence and concentration of MHC 
class II and BCR–Ag complexes into lysosomes devoted 
to Ag processing. Accordingly, the formation of MHC 
class II–peptides and subsequent CD4 T cell activation 
are impaired in cells lacking myosin II activity. Therefore, 
myosin II emerges as a key motor protein in BCR-driven 
Ag processing and presentation.
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essential function of the BCR: Ag captured through the BCR 
undergoes accelerated transport to endosomes and enhanced 
presentation effi  ciency as compared with Ag taken up by fl  uid-
phase endocytosis (Aluvihare et al., 1997; Cheng et al., 1999b). 
Translocation of BCR–Ag complexes to lipid rafts as well as an 
intact actin cytoskeleton have been proposed to be essential for 
accelerated transport to endosomes (Barois et al., 1998; Cheng 
et al., 1999a; Brown and Song, 2001). In addition, this process 
is accompanied by substantial modifi  cations in the endocytic 
pathway of B cells, as highlighted by studies using various 
mouse lymphoma cell lines (Siemasko et al., 1998;  Zimmermann 
et al., 1999; Lankar et al., 2002). In particular, we and others 
have shown that intracellular MHC class II molecules and BCR-
internalized Ag converge into nonterminal LAMP-1–containing 
lysosomal compartments that display a multivesicular morphol-
ogy and wherein Ag processing occurs, a process that depends on 
MHC class II–associated Ii (Siemasko et al., 1998; Zimmermann 
et al., 1999; Lankar et al., 2002).
The molecular mechanisms involved in the biogenesis of 
multivesicular endosomes have been documented, in particular 
by highlighting the importance of ubiquitylation in targeting 
membrane proteins to multivesicular endosome luminal vesicles 
(Raiborg et al., 2003). The key role of Ag-triggered BCR ubiqui-
tylation in directing Ag traffi  cking toward multivesicular lyso-
somes enriched for MHC class II was recently reported (Drake 
et al., 2006). In addition, differential ubiquitylation of MHC class II 
β chain was shown to regulate its surface expression in immature 
versus mature dendritic cells (DCs; Shin et al., 2006). However, 
little information is available on the nature of the motor proteins 
that connect the vesicles carrying MHC class II molecules to the 
cytoskeleton, thereby helping their sorting to lysosome-like multi-
vesicular compartments. This could involve microtubule- and/or 
actin-dependent forces, which are both known to control in 
  concert the intracellular location and traffi  cking of organelles.
We aimed to understand how BCR engagement in pri-
mary lymphocytes coordinates the transport of Ag- and MHC 
Figure 1.  BCR stimulation induces the convergence of BCR-internalized Ag and MHC II molecules in LAMP-1–containing vesicles that cluster toward the cell center. 
(A and C–E) Confocal images of spleen B cells from MHC II–GFP mice. (A) Z sectioning of resting (top) or 1-h BCR-activated (bottom) cells. Resting cells 
  display the peripheral distribution of MHC II–GFP molecules, whereas activated cells contain a central MHC II–GFP
+ cluster. (B) Clustering kinetics of MHC II–
GFP-containing vesicles upon BCR engagement (n = 300 cells per time point; three independent experiments). Error bars represent SD. (C) MHC II–
GFP
+ central clusters are LAMP-1
+ compartments wherein BCR-internalized Ag accumulates. The insets highlight cells coming from the same ﬁ  eld but for 
which different z planes were used to build the ﬁ  nal images. (D) Orthogonal projections of resting and BCR-stimulated MHC II–GFP
+ spleen B cells labeled 
with DAPI. Activated cells display a nuclear invagination where the central MHC II–GFP
+ lysosomal cluster sits. (E) 3D reconstructions of the single cells 
described in C. Bars, 5 μm.MYOSIN II–DEPENDENT ANTIGEN PRESENTATION • VASCOTTO ET AL. 1009
class II–containing vesicles for them to converge and ensure 
effi    cient  Ag processing. In this study, we identify the actin- 
based motor protein myosin II as playing an essential role in 
this   process. Myosin II is activated upon BCR engagement and 
becomes physically associated with MHC class II–Ii complexes. 
Myosin II inhibition or depletion impairs the concentration 
of MHC class II molecules together with BCR–Ag complexes 
into lysosomes devoted to Ag processing. Accordingly, cells 
lacking myosin II activity do not effi  ciently form MHC class II–
peptide complexes from BCR-internalized Ag. Thus, myosin II 
regulates MHC class II traffi   cking and Ag processing in 
B lymphocytes.
Results
BCR engagement induces clustering 
of MHC class II– and Ag-containing 
vesicles near the cell center
BCR stimulation of mouse B lymphoma cell lines triggers the 
appearance of MHC class II–containing compartments wherein 
BCR-internalized Ag is processed (Siemasko et al., 1998; 
  Lankar et al., 2002). To explore the mechanisms underlying 
this process in primary B lymphocytes, we used MHC II–GFP 
knockin mice (Boes et al., 2002). B cells purifi  ed from the 
spleen of MHC II–GFP mice were or were not BCR stimulated 
with a polyvalent BCR ligand (hereafter referred to as Ag) and 
analyzed by confocal microscopy. Resting B cells exhibited the 
peripheral distribution of MHC II–GFP molecules (Fig. 1 A), 
which was reminiscent of both surface and intracellular local-
ization (in both lysosomes and the ER; see the next paragraph; 
not depicted). In sharp contrast, BCR engagement induced the 
redistribution of MHC II–GFP-containing vesicles that clus-
tered near the cell center (Fig. 1 A). A substantial change in 
the nuclear shape of BCR-activated lymphocytes was also 
  observed: whereas the nucleus of resting cells was round and 
fi  lled most of the intracellular space, the vast majority of stimu-
lated B cells displayed an important nuclear invagination where 
the MHC-GFP
+ cluster sits (Fig. 1 D). Kinetics of MHC II–GFP 
clustering showed a peak at 60 min upon BCR triggering for 
 70% of the cells (Fig. 1 B). A similar observation was 
recently made using MHC class II–GFP knockin mice express-
ing a specifi  c BCR and stimulated with a polyvalent Ag (Kim 
et al., 2006).
MHC class II
+/Ag
+ clusters displayed the features of 
lysosomal-like Ag processing compartments: they stained posi-
tive for BCR–Ag complexes, LAMP-1, and H2-DM (Fig. 1, 
C and E; and Fig. S1 A, available at http://www.jcb.org/cgi/ 
content/full/jcb.200611147/DC1) but contained reduced amounts 
of full-length Ii (Fig. S1 A). Accordingly, BCR stimulation in-
duced the rapid cleavage of MHC II–bound Iip31 as indicated 
by the appearance of the Ii proteolytic intermediary fragments 
Iip25 and Iip10 (Fig. S1 B). No substantial change in the steady 
state levels of surface MHC class II was observed at any 
time period between 5 and 60 min upon BCR engagement (Fig. 
S1 C). Although this result does not exclude the possibility 
that MHC class II molecules are transported to lysosomes by 
traffi  cking through the cell surface, it indicates that the MHC 
class II
+/Ag
+ lysosomal cluster does not result from massive 
BCR-induced endocytosis of surface MHC class II molecules. 
Ultrastructural experiments showed that MHC class II
+/Ag
+ 
clusters corresponded to a network of vesicles and tubules, 
which included variable amounts of internal membranes en-
riched for MHC class II, LAMP-1, and H2-DM molecules (Fig. 2 
and not depicted). No such compartment was observed in 
resting B cells (unpublished data). Therefore, we conclude that 
similar to mouse B lymphoma cells (Siemasko et al., 1998; 
Lankar et al., 2002), BCR-stimulated primary lymphocytes rap-
idly reorganize their endocytic route, accumulating lysosomal 
compartments that cluster near the center of the cell and to 
which MHC class II molecules and BCR–Ag complexes con-
verge for processing.
Clustering of MHC II
+/Ag
+ lysosomes 
in BCR-stimulated cells is coupled 
to myosin II activation
We next used time-lapse video microscopy to analyze the 
  dynamics of BCR-induced clustering of MHC class II–GFP
+ 
vesicles. Purifi  ed spleen MHC II–GFP
+ B cells were or were not 
Figure 2.  Immunogold cryoelectron microscopy analysis 
of 1-h BCR-stimulated MHC II–GFP
+ spleen B cells. The 
central cluster containing MHC II–GFP molecules cor-
responds to a tubular and vesicular network of LAMP-1
+ 
lysosomes. Sections were labeled using 10-nm and 15-nm 
immunogold particles for MHC class II and LAMP-1 mole-
cules, respectively. The boxed area is magniﬁ   ed in the 
right bottom panel.JCB • VOLUME 176 • NUMBER 7 • 2007  1010
BCR stimulated and analyzed by 3D deconvolution time-lapse 
fl  uorescence microscopy. MHC II–GFP
+ vesicles showed ran-
dom movements in resting B cells and did not experience any 
substantial change in morphology during the duration of image 
acquisition (Video 2; available at http://www.jcb.org/cgi/ 
content/full/jcb.200611147/DC1). In contrast, Ag-activated 
B lymphocytes exhibited major morphological changes during 
time-lapse (see Video 1 for general fi  eld and Video 3 for single 
cell). Strikingly, the plasma membrane of the vast majority 
of B cells underwent successive contraction events after BCR 
engagement (Fig. 3 A and Videos 1 and 3). We consistently 
  observed that cell contraction was coupled to MHC II–GFP 
clustering: MHC II–GFP clusters transiently associated with a 
contracted membrane portion and then moved toward the center 
of the cell (Fig. 3 A, arrowheads). Importantly, the centripetal 
movement of MHC II–GFP clusters occurred concomitantly 
to contraction arrest followed by cell spreading (Fig. 3 A 
and Video 3). We conclude that the dynamics of MHC class II–
containing vesicle clustering are coupled to BCR-induced 
cell contractility.
Cell contractility is controlled by the actomyosin network 
and relies, in part, on phosphorylation of the regulatory myosin II 
light chain (MLC). MLC phosphorylation allows the activation 
of myosin II, which then initiates contraction by moving on 
actin microfi  laments (Bresnick, 1999). To investigate whether 
myosin II was activated upon Ag stimulation, we analyzed the 
levels of phosphorylated MLC in resting and activated spleen 
B lymphocytes. Immunoblot experiments performed with an 
antibody (Ab) that specifi  cally recognizes phosphorylated MLC 
showed that BCR stimulation considerably increased MLC 
phosphorylation (Fig. 3 B). MLC phosphorylation showed 
kinetics that was consistent with its potential implication in the 
BCR-induced clustering of MHC class II
+ vesicles, reaching 
maximal levels at 60 min upon BCR engagement (threefold as 
compared with nonactivated B cells).
Analysis of the subcellular distribution of MLC showed 
that although resting cells exhibited homogenous peripheral 
MLC distribution, a 30-min BCR stimulation induced the con-
centration of MLC in contracted cell portions, as contractile 
Figure 3.  Clustering of MHC II–containing lysosomes in acti-
vated B cells is coupled to cell contraction and myosin II 
  activation. (A) 2-h time-lapse analysis of puriﬁ  ed MHC II–GFP
+ 
spleen B cells whose BCR was engaged when starting image 
collection. Deconvolved inverted grayscale z-stack projec-
tions of sequential images (a–g) from a single BCR-stimulated 
cell, which shows multiple membrane contraction events, are 
displayed (Video 3, available at http://www.jcb.org/cgi/
content/full/jcb.200611147/DC1). Arrowheads indicate con-
tracted membrane portions. (B) Cell lysates from B cells 
  activated for different time periods with BCR polyvalent lig-
ands were analyzed by immunoblotting using antiphospho-
MLC (top) and anti-MLC Abs (bottom). Levels of phospho-MLC 
were quantiﬁ  ed with ImageJ software (National Institutes of 
Health) and normalized for the relative intensity of total MLC. 
(C) Confocal images of ﬁ  xed MHC II–GFP
+ spleen B cells 
labeled with anti-MLC and anti-Ii (In-1) Abs. Although resting 
B cells show the homogeneous cytoplasmic distribution of 
MLC, 30 min–stimulated cells redistribute their MLC molecules 
to contracted cell poles, where they colocalize with MHC II–GFP 
and Ii. The boxes highlight cells coming from the same slide 
but from a different ﬁ  eld. Bars, 5 μm.
Figure 4.  Myosin II activation is required for the formation of lyso-
somal clusters where MHC class II and Ag converge but is not required 
for BCR capping and internalization. (A) Confocal images obtained from 
MHC II–GFP
+ spleen B cells not pretreated or pretreated with 10 μM 
ML-7 plus 10 μM Y27632 or 70 μM blebbistatin and activated with 
multivalent BCR ligands for 1 h at 37°C. Fixed cells were labeled 
with  the indicated Abs. ML-7/Y27632 or blebbistatin treatment pre-
vents the central clustering of MHC II–GFP
+/LAMP-1
+/Ag
+ vesicles. 
Insets show cells coming from the same slide but from different ﬁ  elds. 
(B) 3D reconstructions of the single cells described in A. (C) Quantiﬁ  ca-
tion of the experiment described in A (n = 200; three independent 
experiments). Histogram bars represent the percentage of activated 
B cells that show central (black) or peripheral (white) MHC II–GFP
+/Ag
+ 
vesicles. (D) BCR internalization kinetics in spleen B cells not treated or 
treated with ML-7/Y27632 or blebbistatin and stimulated with BCR 
polyvalent ligands. The levels of plasma membrane IgM (mIgM) were 
assessed by cytoﬂ  uorometry on B220
+ gated cells. Histogram bars rep-
resent mean ﬂ   uorescence intensity ratios between BCR-activated and 
resting B cells from three different experiments. Error bars represent SD. 
Bars, 5 μm.MYOSIN II–DEPENDENT ANTIGEN PRESENTATION • VASCOTTO ET AL. 1011
rings were often appreciated (Fig. 3 C). Both MHC II–GFP and 
Ii were enriched in such contraction sites together with MLC 
molecules (Fig. 3 C, bottom). This fi  nding strengthens the time-
lapse results showing that before moving toward the center of 
the cell, clusters of MHC class II
+ vesicles transiently associate 
with contractile membrane portions. Thus, BCR stimulation of 
resting mature lymphocytes triggers myosin II activation as indi-
cated by MLC phosphorylation and redistribution to contracted 
membrane portions, where it colocalizes with MHC class II
+ 
vesicle clusters.
Myosin II activity is required for the 
clustering and maturation of lysosomes 
wherein MHC class II molecules and 
BCR–Ag complexes concentrate
To demonstrate that myosin II–driven contraction is indeed 
functionally required for BCR-induced clustering of MHC 
class II– and Ag-containing vesicles, we fi  rst used pharmacol-
ogical inhibitors. The inhibitors Y27632 and ML-7 target RhoA 
effector kinase (Rho-associated kinase) and MLC kinase, 
  respectively (Kimura et al., 1996). Rho-associated kinase inhibits 
MLC-phosphatase and, thereby, indirectly promotes the levels 
of phosphorylated MLC, a task performed by MLC kinase 
(Kimura et al., 1996). Blebbistatin is a highly specifi  c inhibitor 
of the ATPase activity of myosin II that has been used to dem-
onstrate its involvement in cell division and migration (Straight 
et al., 2003; Rosenblatt et al., 2004; Gomes et al., 2005; Gupton 
and Waterman-Storer, 2006). Time-lapse experiments showed 
that when spleen B cells were pretreated for 45 min with 
these inhibitors before Ag stimulation, they underwent neither 
contraction nor cell spreading (Videos 4 and 5, available at 
http://www.jcb.org/cgi/content/full/jcb.200611147/DC1).
Prevention of myosin II activation or inhibition of its ac-
tivity strongly impaired the clustering of MHC class II– and Ag-
containing lysosomes at the center of BCR-stimulated spleen 
B cells (Fig. 4, A and B). Only a few clusters were observed in 
drug-treated activated cells, and they seemed to contain reduced 
amounts of MHC class II, LAMP-1, and Ag molecules. In 
addition, these clusters remained dispersed at the cell periph-
ery rather than concentrated at the center of myosin II–inhibited 
cells (Fig. 4, A and B). Quantitative analysis showed that al-
though  75% of control Ag-stimulated cells displayed MHC II–
GFP
+/LAMP-1
+/Ag
+ central clusters, only  15% did when 
myosin II activation was hampered (n  = 200; Fig. 4 C). 
Impaired clustering did not result from a defect in Ag-induced 
BCR capping or internalization, which remained unaffected in 
the presence of myosin II inhibitors, excluding a general paralysis 
induced by drug treatment (Fig. 4 D and Fig. S2, available 
at http://www.jcb.org/cgi/content/full/jcb.200611147/DC1). 
No effect of myosin II inhibition on MHC class II surface lev-
els was observed by cytofl  uorometry (unpublished data). Thus, 
MHC class II– and Ag-containing vesicles do not converge 
and cluster together at the cell center when myosin II activity 
is compromised.
Having shown that myosin II activity is required for 
the proper positioning of MHC II
+/Ag
+ compartments, we next 
Figure 5.  Myosin II activation is required to 
concentrate Ag and MHC II molecules into clus-
tered lysosomes. (A–C) Cryoimmunoelectron 
microscopy analysis of 1 h–activated spleen 
B cells pretreated with DMSO (A and C) or 
ML-7 plus Y27632 (10 μM of each; B and C, 
inset) and labeled for MHC II (10 nm gold par-
ticles) and LAMP-1 molecules (A and B) or Ag 
(C). Activated cells display a network formed 
of LAMP-1
+ tubular and vesicular lysosomes 
wherein the Ag and MHC class II molecules 
concentrate together (A and C). Myosin II–
inhibited cells show vacuolar compartments 
that label for Ag, MHC II, and LAMP-1 at their 
limiting membrane (B and C, inset). PM, plasma 
membrane. Bars, 200 nm. (D) Immunoblotting 
of the nonmagnetic (NMF) and magnetic frac-
tions (MF) obtained from spleen B cells not 
pretreated or pretreated with blebbistatin, 
stimulated with magnetic NP coupled to F(ab′)2 
anti-BCR Abs, and mechanically lysed. Semi-
puriﬁ   ed Ag-containing endosomes were ob-
tained after magnetic separation as described 
in Materials and methods. Enrichment for 
MHC class II and Ii in the magnetic fraction is 
decreased in blebbistatin-treated cells. The lev-
els of cathepsin D (proform and mature) and 
Rab5 in the magnetic fraction are not affected 
by blebbistatin treatment.JCB • VOLUME 176 • NUMBER 7 • 2007  1012
addressed by immunogold cryoelectron microscopy whether it 
also affects the maturation of these vesicles. The network of tu-
bular and vesicular lysosomes wherein LAMP-1, H2-DM, Ag, 
and MHC class II molecules accumulate was barely observed in 
cells lacking myosin II activity (Fig. 5, A and C). Instead, drug-
treated BCR-stimulated lymphocytes showed vacuolar compart-
ments that labeled for LAMP-1, Ag, or MHC class II molecules 
at their limiting membrane (Fig. 5, B and C; inset). Consistent 
with immunofl  uorescence experiments, these vacuolar compart-
ments were dispersed in the cytoplasm of drug-treated cells 
rather than clustered together, leading to the reduced concentration 
of MHC class II molecules and Ag in their lumen as compared 
with control BCR-stimulated lymphocytes (see Table I for 
quantifi  cations). Thus, the lack of myosin II activity affects the 
maturation of lysosomes to which MHC class II molecules and 
BCR–Ag complexes are targeted.
The impact of myosin II inhibition on the maturation of 
MHC II
+/Ag
+ lysosomes was further investigated by biochemi-
cal means using magnetic nanoparticles (NPs) coupled to anti-
BCR Abs. As shown by Perrin-Cocon et al. (2004), these NPs 
undergo proper BCR-mediated uptake and targeting to MHC 
class II–containing lysosomes (Fig. S3, available at http://www
.jcb.org/cgi/content/full/jcb.200611147/DC1), allowing us to semi-
purify the endocytic compartments in which they accumulate 
(Fig. 5 D). We found that both the amounts of MHC class II 
and Ii were strongly decreased in endosomes purifi  ed from 
BCR-stimulated cells whose myosin II activity was compro-
mised (Fig. 5 D). In contrast, levels of the early endosomal 
marker Rab5 and of lysosomal mature cathepsin D found in the 
magnetic fraction were not affected by the lack of myosin II 
  activity (Fig. 5 D). In conclusion, both our morphological and 
biochemical results indicate that myosin II is required for 
the proper traffi  cking and maturation of MHC class II– and 
Ag-containing vesicles: it promotes their clustering in activated 
B lymphocytes and, thereby, allows them to concentrate together 
into a multivesicular and tubular lysosomal network.
Myosin II activity is required 
for BCR-driven Ag presentation
We next assessed whether myosin II activity is required for the 
presentation of BCR-internalized Ag using both B lymphoma 
cells and primary B lymphocytes. A20/DNP cells were pre-
treated with Y27632 and/or ML-7, further incubated with oval-
bumin (OVA)-DNP (DNP-OVA), fi  xed, and cultured together 
with OVA-responding T cell hybridoma (Peterson and Miller, 
1990). Pretreatment of A20/DNP cells with drugs that prevented 
myosin II activation or activity inhibited OVA presentation 
to CD4
+ T cells in a dose-dependent manner (Fig. 6, A, B, and D). 
Equivalent results were obtained when targeting OVA protein 
to the BCR of spleen B cells by chemically cross-linking it to 
anti-IgM F(ab′) fragments (Fig. 6 C). No presentation of non-
coupled OVA was detected under such experimental conditions, 
showing that the effect of the drugs indeed concerned the pre-
sentation of BCR-internalized Ag (Fig. 6 C). Importantly, the 
presentation of exogenously added OVA323–339 peptide was not 
affected by any drug treatment, demonstrating that the inhibi-
tion of Ag presentation resulted from impaired processing 
(Fig. 6, A, C, and D). Pulse-chase experiments performed on 
Ag-stimulated spleen B cells not treated or treated with the 
drugs showed that synthesis, maturation, and processing of 
MHC II molecules were not compromised upon myosin II 
 inhibition:  equivalent amounts of SDS αβ–peptide complexes 
were immuno  precipitated from control and drug-treated cells. 
This indicates that the basal interaction of neosynthesized 
MHC II molecules with endogenous peptides does not require 
Figure 6.  Myosin II activity is required for BCR-driven Ag 
presentation. (A and B) A20 cells expressing an anti-DNP sur-
face IgM were pretreated with ML-7, Y27632, or DMSO for 
45 min, incubated with DNP-OVA (increasing amounts [A] 
or 10 μg/ml [B]) or 20 μg/ml OVA323–339 peptide for 4 h, 
washed, and ﬁ   xed. T cell activation was measured as de-
scribed in Materials and methods. T cell proliferation in re-
sponse to DNP-OVA presentation is inhibited by the inhibitor 
treatment in a dose-dependent manner. (C) Spleen B cells pre-
treated with Y27632 or DMSO for 45 min at 37°C were in-
cubated with anti-IgM F(ab′) chemically cross-linked to OVA, 
noncoupled OVA, anti-IgM F(ab′)2, or with OVA peptide for 
4 h and were washed and ﬁ  xed. (D) The experiment was per-
formed as in A but not pretreating or pretreating the cells 
with blebbistatin.
Table I. Inhibition of myosin II activity reduces the amount of Ag and 
MHC class II molecules that concentrate together in lysosomes
Ag MHC II Ratio of 
Ag/MHC II
DMSO-treated cells 200 663 0.302
ML-7/Y27632-
 treated cells
28 288 0.123
Quantiﬁ  cation of the immunogold cryoelectron microscopy experiments shown 
in Fig. 5. Gold particles from 30 compartments were counted in randomly 
selected B cell proﬁ  les. We could estimate that the compartments presenting 
vacuolar empty morphology in drug-treated cells represent  70% of the 
total compartments observed. No vacuolar compartment was observed in non-
treated cells.MYOSIN II–DEPENDENT ANTIGEN PRESENTATION • VASCOTTO ET AL. 1013
myosin II activity, whereas the processing of BCR-internalized 
Ag strictly relies on it (Fig. S4, available at http://www.jcb.org/
cgi/content/full/jcb.200611147/DC1). Thus, the activity of the 
actin-associated motor myosin II is strictly required for BCR-
driven Ag presentation.
Myosin II is required for the formation 
of MHC II–peptide complexes 
from BCR-uptaken Ag
Is myosin II necessary for the formation of MHC II–peptide 
complexes from BCR-uptaken Ag, or is it required to export 
these complexes to the cell surface for interaction with T cells? 
To address this question, we took advantage of the mAb 2C44 
that specifi  cally recognizes the complexes formed between I-A
d 
molecules and the 156–173 peptide from Leishmania major Ag 
LACK but does not bind to any of the free components (Lazarski 
et al., 2006). Recombinant LACK protein was targeted to BCR 
uptake by coupling it to the aforementioned NP together with 
anti-BCR Abs. The appearance of I-A
d–LACK156–173 complexes 
was analyzed by immunofl  uorescence using 2C44 at 2 and 4 h 
upon Ag internalization. At both time points, I-A
d–LACK156–173 
complexes were mainly detected in lysosome clusters that 
  labeled for LAMP-1 (Fig. 7 A). No complex formation was ob-
served when using NPs only coupled to LACK or to anti-BCR 
Abs (Fig. 7 B and not depicted).
This assay was used to assess the requirement of myosin II
activity on the formation of MHC II–peptide complexes. Bleb-
bistatin treatment strongly reduced the percentage of 2C44
+ 
cells, indicating that myosin II activity is indeed necessary for 
the formation of I-A
d–LACK156–173 complexes (see Fig. 7, A and 
B for quantifi  cations). Moreover, the few 2C44
+ blebbistatin-
treated cells displayed staining in peripherally distributed lyso-
somes rather than in central clusters (Fig. 7 A). Impairment of 
I-A
d–LACK156–173 complex formation in myosin II–inhibited 
cells was further confi  rmed biochemically by showing that they 
contained reduced 2C44-reactive material after immunoprecipi-
tation as compared with mock-treated lymphocytes (Fig. 7 C).
To introduce genetic evidence in the involvement of myo-
sin II in the formation of MHC II–peptide complexes, we per-
formed depletion experiments using siRNA. RT-PCR analysis 
had shown that MyH9 was a major myosin II form expressed in 
mouse B lymphoma cells (unpublished data). Three myosin IIA 
Figure 7.  Myosin II is required for the formation of 
MHC II–peptide complexes. (A–C) Blebbistatin inhibits 
the formation of I-A
d–LACK156–173 complexes. (A) Con-
focal images of IIA1.6 cells not pretreated or pre-
treated with 70 μM blebbistatin and activated for 4 h 
at 37°C with NP coupled to recombinant LACK pro-
tein and F(ab′)2 anti-BCR Abs in a 1:1 molarity ratio. 
Cells were ﬁ  xed and labeled with the indicated Abs. 
Peptide LACK156–173 was used as a positive control for 
2C44 staining (bottom). Insets show cells coming from 
the same slide but from different ﬁ  elds. (B) Quantiﬁ  ca-
tion of the experiment described in A (n = 300; three 
independent experiments). Histogram bars represent 
the percentage of activated B cells that contain I-A
d–
LACK156–173 complexes. NPs were coupled to anti-BCR 
F(ab′)2 Abs alone (NP) or together with recombinant 
LACK protein. Error bars represent SD. (C) IIA1.6 cells 
not pretreated or pretreated with blebbistatin were ac-
tivated as described in A. Peptide LACK156–173 was 
added to the cells for 4 h at 37°C as a positive control. 
Cells were lysed, immunoprecipitated with 2C44, and 
analyzed by immunoblotting for the presence of I-Aβ. 
In parallel, equal amounts of cell extracts were ana-
lyzed by immunoblotting for α-tubulin expression. Ver-
tical lines indicate gel image cuts. (D–F) Myosin II 
depletion by siRNA impairs lysosome clustering and 
formation of I-A
d–LACK156–173 complexes. (D) IIA1.6 
cells were transfected with different siRNAs speciﬁ  c 
for myosin IIA (MyH9 gene; pool of three single siRNAs) 
or with a control siRNA and incubated at 37°C for 
96 h. Cells were lysed, and equal amounts of cell 
lysates were analyzed by immunoblotting for the 
presence of myosin II heavy chain. α-Tubulin was used 
as a loading control. (E) Confocal images of IIA1.6 
cells transfected for 96 h with control or the pool of 
MyH9 siRNAs, activated for 4 h, ﬁ  xed, and stained as 
described in A. Arrowheads indicate peripheral lyso-
some patches in MyH9-depleted cells. The boxed ar-
eas are magniﬁ  ed in F. (F) Magniﬁ  ed images of the 
single cells shown in E. (G) Quantiﬁ  cation of the ex-
periments described in E (n = 300; two independent 
experiments). Histogram bars represent the percent-
age of activated B cells that contain I-A
d–LACK156–173 
complexes. Error bars represent SD. Bars, 5 μm.JCB • VOLUME 176 • NUMBER 7 • 2007  1014
(MyH9)–specifi  c siRNAs were electroporated into B lympho-
cytes either individually or as a pool. MyH9 depletion was ob-
tained with the three individual siRNAs and even more effi  ciently 
when using the siRNA pool (Fig. 7 D). The percentage of 2C44
+ 
cells was considerably reduced by MyH9 depletion (see Fig. 
7, E–G for quantifi  cations), demonstrating that the absence 
of   myosin II severely compromised the formation of I-A
d–
LACK156–173 complexes from BCR-internalized LACK. As 
expected, MyH9 depletion reduced the frequency of central 
lysosome clusters (Fig. 7, E and F). In addition, certain MyH9-
depleted cells exhibited peripheral LAMP-1
+ patches similar to 
the ones observed in stimulated primary B cells whose myosin 
II activity was compromised (Fig. 7 E, arrowheads). Therefore, 
we conclude that myosin II is essential for the effi  cient forma-
tion of MHC II–peptide complexes from BCR-internalized Ag.
MHC II–Ii complexes and 
myosin II dynamically associate 
upon BCR engagement
Having established that myosin II activity regulates the traffi  cking 
of MHC class II molecules upon BCR engagement, we next in-
vestigated whether these proteins physically associate. The traf-
fi  cking of MHC class II molecules mainly relies on the cytosolic 
portion of its chaperone-associated molecule, Ii, which is es-
sential for the processing and presentation of BCR-internalized 
Ag (Zimmermann et al., 1999). Thus, we raised the hypothesis 
that Ii may physically link MHC class II–containing vesicles to 
myosin II through its cytosolic tail. In support of this hypoth-
esis, B cells stimulated for short time periods showed a strong Ii 
staining in the contracted membrane portions and the contrac-
tile rings to which MLC and MHC class II molecules were 
  recruited (Fig. 3 C) as well as Ii/MLC colabeling in membranes 
from ER, Golgi, and endocytic vesicles when analyzed by 
immunogold cryoelectron microscopy (Fig. S5, available at 
http://www.jcb.org/cgi/content/full/jcb.200611147/DC1).
Moreover, MLC was pulled down in the aforementioned 
B lymphoma cell line by using anti-Ii Abs in coimmunoprecipi-
tation experiments (Fig. 8 A). MHC class II molecules were 
also found in anti-Ii immunoprecipitates. Strikingly, MLC–Ii 
complexes were retrieved from BCR-stimulated cells only. The 
interaction was found to be transient, and its kinetics was com-
patible with the one observed for MHC II
+ vesicle clustering, 
reaching maximal levels at 60 min and then decaying. In agree-
ment with this observation, the amounts of Ii-associated actin 
increased with similar kinetics as well (Fig. 8 A). MLC was also 
retrieved when using anti-MHC II Abs for the immunoprecipi-
tation (Fig. 8 B). Importantly, the inhibition of myosin II activity 
with blebbistatin reduced its ability to associate with MHC class 
II–Ii complexes (Fig. 8 B). These results show that MHC II–Ii 
complexes and myosin II dynamically associate upon BCR 
engagement and further indicate that BCR-triggered myosin II 
activity is necessary for this association.
Association of MHC class II 
to myosin II requires Ii
Are both Ii and MHC class II required for the association to 
myosin II? Because insuffi  cient protein amounts are generated 
from mouse spleen B cells, we used DCs purifi  ed from either 
Ii- or MHC II (I-Aβ)–defi  cient mice to address this question. 
Indeed, a 30-min lipopolysaccharide (LPS) stimulation of DCs 
induces the dynamic association between MHC class II–Ii and 
myosin II, as observed in BCR-activated cells (unpublished data). 
We found that the interaction between MHC class II and MLC 
was completely abolished in Ii-defi  cient cells (Fig. 9 A). This 
equally applies to myosin II heavy chain (MyH9) as observed 
when immunoprecipitating Ii and analyzing the coimmuno-
precipitated material by immunoblotting or by an unbiased detec-
tion method (Coomassie staining followed by mass spectrometry 
analysis). Indeed, MyH9 is the major protein retrieved in this ex-
periment, and its levels are comparable with those of immuno-
precipitated Ii (Fig. 9 C). Strikingly, Ii retained the capacity to 
associate to MLC in I-Aβ knockout cells, although less effi  ciently 
(Fig. 9 A). No difference in the expression levels of MLC or myo-
sin II heavy chain was observed in total extracts from I-Aβ– or 
Ii-defi  cient cells (Fig. 9 B). Together, these results show that Ii is 
essential for MHC II–Ii–myosin II interaction and further sug-
gests that this association links MHC class II–containing vesicles 
to the actin network. In support of this conclusion, we found that 
Ii-defi  cient BCR-stimulated lymphocytes exhibited the peripheral 
distribution of MHC II–, LAMP-1–, and Ag-containing vesicles 
instead of central clusters, which is similar to cells whose myosin 
II activity was compromised (Fig. 9 E).
Figure 8.  MHC class II–Ii complexes and myosin II transiently associate 
upon BCR engagement. (A and B) Coimmunoprecipitation experiments 
showing dynamic MHC class II–Ii–MLC association upon BCR engagement. 
IIA1.6 cells were activated with multivalent BCR ligands and lysed in a 
0.5% NP-40–containing buffer, and immunoprecipitations were performed 
using anti-Ii (In-1; A) or anti–MHC II Abs (M5114; B). Immunoprecipitates 
were analyzed by immunoblotting for the presence of MLC, actin, Ii, or 
MHC II (I-Aβ). Myosin II inhibition by 70 μM blebbistatin reduces MHC 
II–Ii–myosin II association (B). Quantiﬁ  cations were performed with ImageJ 
software, and values were normalized to the immunoprecipitated protein 
levels and expressed relative to the signal intensity obtained from non-
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Two nonexclusive hypotheses can be raised to explain the 
lack of MHC II–myosin II association in Ii-defi  cient cells: it 
could result from (1) MHC II mislocalization, which accumu-
lates in the ER when Ii is missing (Koonce and Bikoff, 2004; 
unpublished data), or (2) the requirement for Ii cytosolic tail to 
form a complex with myosin II. The fact that Ii retains its abi-
lity to associate to myosin II in the absence of MHC class II 
molecules argues in favor of the second hypothesis. To further 
analyze the involvement of Ii cytosolic tail in the association 
with myosin II, we took advantage of the specifi  c inhibitor of 
cathepsin S, LHVS, which prevents the removal of Ii cytosolic 
tail from MHC II–Ii complexes that have reached LAMP-1
+ 
compartments (Brachet et al., 1997; Driessen et al., 1999). 
LHVS-treated cells displayed modifi  ed kinetics of MHC II–
myosin II association: although 60 min upon BCR activation, 
the retrieval of myosin II with anti–MHC II Abs was diminished 
as compared with untreated cells, the association was still main-
tained 120 min upon BCR engagement (Fig. 9 D). This result 
shows that the presence of the cytosolic tail of Ii on MHC II–Ii 
complexes in lysosomes regulates their ability to associate with 
myosin II. We conclude that the lack of association of MHC II 
to MLC in Ii- defi  cient cells likely refl  ects the direct involve-
ment of Ii in the formation of this protein complex rather than 
from the mislocalization of MHC class II molecules. Our data 
further indicate that MHC II–Ii–myosin II association can be 
modifi  ed by inhibiting myosin II activity with blebbistatin as 
well as by altering the processing of MHC II–Ii complexes with 
LHVS, providing strong evidence in favor of a direct role for 
myosin II in regulating MHC class II traffi  cking.
Discussion
In this study, we show that BCR engagement deeply modifi  es 
the endocytic pathway of B cells by inducing the formation of 
lysosome clusters wherein MHC class II molecules and BCR–
Ag complexes converge. This process relies on the motor pro-
tein myosin II. We propose that BCR engagement triggers 
myosin II activation and association with MHC class II–Ii com-
plexes, allowing them to be transported toward incoming BCR-
associated Ag. This event of polarized traffi  cking would allow 
MHC class II and BCR–Ag complexes to concentrate together 
in lysosomal compartments devoted to Ag processing that clus-
ter near the cell center. The association between MHC class II–Ii 
complexes and myosin II is likely to be mediated by Ii cytosolic 
tail and, thus, is likely to be favored by the previously reported 
BCR-triggered down-regulation of cathepsin S activity, which 
  allows the transient accumulation of MHC II–Ii complexes that 
retain Ii cytosolic tail (Lankar et al., 2002). Once in lysosome 
clusters, the proteolysis of Ii, which, as shown in Fig. S1, is trig-
gered upon BCR engagement, would help myosin II to dissoci-
ate from MHC class II–containing vesicles. Accordingly, 
inhibition of myosin II activity prevents the concentration of MHC 
class II and Ag–BCR complexes in clustered lysosomes as well 
as the subsequent formation of MHC class II–peptide complexes 
and presentation to T cells. Therefore, myosin II emerges as the 
fi  rst motor protein to be involved in Ag-regulated traffi  cking of 
MHC class II molecules.
Is myosin II–driven cell contraction required 
for BCR-driven Ag processing?
Myosin II is known to mediate cellular contractility. Our video 
microscopy experiments show that BCR-stimulated lympho-
cytes display major contractile activity, which is suppressed 
when inhibiting myosin II activation. Does cell contraction me-
diate the clustering of MHC II–containing lysosomes? Although 
we cannot directly address this question, we do favor this hypo-
thesis based on the following observations: (1) the clusters of 
Figure 9.  Ii is required for MHC II–myosin II association. (A–D) Coimmuno-
precipitation experiments highlighting the key role of Ii in MHC II–MLC 
association. (A) Bone marrow–derived DCs from wild-type (WT), Ii-, or 
I-Aβ–deﬁ  cient mice were treated with LPS for 30 min and lysed in a 0.5% 
NP-40–containing buffer, and immunoprecipitations were performed as 
described in Fig. 7. (B) Immunoblotting analysis of extracts from bone 
marrow–derived DCs from wild-type, Ii-, or I-Aβ–deﬁ  cient mice. Cell were 
treated with LPS for 30 min and lysed in a 0.5% NP-40–containing buffer. 
10 μg of protein was loaded per lane. I-Aβ glycosilation is impaired in 
Ii-deﬁ  cient cells, and total levels of Ii are increased in extracts from DCs 
lacking I-Aβ. (C) Coomassie blue–stained gel (top) and immunoblotting 
experiment (bottom) showing the association of Ii with myosin II heavy 
chain. Bone marrow–derived DCs from wild-type or Ii-deﬁ  cient mice were 
treated as described in A, and anti-Ii immunoprecipitations were performed 
using the In-1 Ab. Dotted line indicates a gel image cut. (D) Modiﬁ  cation 
of the presence of MHC II–associated Ii cytosolic tail by LHVS treatment 
alters the kinetics of MHC II–myosin II interaction. IIA1.6 cells were not 
pretreated or pretreated with 5 nM LHVS or latrunculin B, activated 
with  multivalent BCR ligands, and lysed in a 0.5% NP-40–containing 
buffer, and immunoprecipitations were performed using anti–MHC II Abs 
(M5114). The top band shown with an asterisk in latrunculin-treated sam-
ples corresponds to the light chain of the membrane Ig, which is further sol-
ubilized during lysis when the actin cytoskeleton is disrupted. (E) Confocal 
images obtained from spleen puriﬁ  ed B cells of Ii
+/+ and Ii
−/− mice acti-
vated with multivalent BCR ligands for 1 h that were ﬁ  xed and stained with 
the indicated Abs. The lack of Ii molecules prevents the clustering of MHC 
II
+/Ag
+ lysosomes toward the cell center similarly to myosin II inhibition. 
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MHC class II–GFP
+ vesicles were consistently found in associ-
ation with contracted membrane portions during live imaging; 
(2) the regulatory subunit of myosin II was relocalized together 
with MHC II–Ii complexes to these contracted areas in ex-
periments on fi  xed cells; and (3) the kinetics of MHC II–Ii–
myosin II interaction was compatible with the one followed by 
cell contraction.
An attractive hypothesis would be to propose that acto-
myosin contractility would create the forces required for B cells 
to extract Ag from target cell membranes (Batista et al., 2001). 
Indeed, it is thought that in vivo, B lymphocytes mainly acquire 
Ag in a membrane-bound form from cells in charge of trans-
porting them from the periphery to the lymph nodes (Qi et al., 
2006). The acquisition of membrane-bound Ag by B cells is 
  dependent on the interaction of the ICAM-1/LFA-1 adhesion 
molecules (Carrasco et al., 2004), which were shown to trigger 
actomyosin contraction in other cell types (Smith et al., 2003). 
Interestingly, we often observed contacts between Ag-stimulated 
B cells undergoing contractions during our time-lapse experi-
ments (Video 1). Therefore, ICAM-1/LFA-1 might potentiate 
the activation of myosin II at the contact site between B and Ag 
carrier cells and, thereby, couple BCR-triggered activation to 
Ag extraction (Carrasco et al., 2004). Accordingly, it was re-
cently demonstrated that extraction of membrane-bound Ag by 
B lymphocytes occurs through a two-phase membrane spreading 
and contraction response (Fleire et al., 2006), which is likely to 
depend on the actomyosin network.
MHC II–Ii–myosin II interaction links MHC II 
trafﬁ  cking to the actomyosin network
The molecular link between MHC class II–containing compart-
ments and the actomyosin network is provided by the dynamic 
interaction between MHC class II–Ii complexes and myosin II, 
which become part of a protein complex that specifi  cally assem-
bles upon BCR engagement and requires myosin II activation 
as well as proper processing and traffi  cking of MHC II–Ii 
complexes. The specifi  city of this protein interaction was con-
fi  rmed by showing that it relies on the strength of BCR signaling 
given that it is substantially impaired in Syk-defi  cient cells (unpub-
lished data). In addition, myosin IIA heavy and light chains 
were recently identifi  ed in a unbiased proteomic approach as 
coimmunoprecipitating with MHC class II molecules in human 
DCs, further strengthening the relevance of the MHC II–myosin II 
association reported in this study by showing that it is conserved 
in human DCs (Benaroch, P., personal communication).
Although we have much evidence suggesting that the 
physical association between MHC class II molecules and myo-
sin II involves the cytosolic tail of Ii, we do not know whether 
this is a direct protein interaction. Interestingly, a comparative 
analysis of the lipid raft proteomics identifi  ed both myosin IIA 
heavy and light chains as becoming associated with lipid rafts 
upon BCR engagement (Gupta et al., 2006). Association to 
membrane microdomains such as lipid rafts has been high-
lighted for both BCR–Ag and MHC class II–Ii complexes 
(Pierce, 2002; Poloso et al., 2004). In addition, a positive cor-
relation between membrane microdomain association, productive 
traffi  cking toward the center of the cell, and Ag presentation by 
MHC class II molecules was recently shown for oligomeric 
BCR ligands (as opposed to monomeric ones; Kim et al., 2006). 
Thus, MHC II–Ii and myosin II might be part of a complex of 
proteins that dynamically forms and associates with membrane 
microdomains upon BCR activation. Because actin dynamics 
were shown to control the BCR-induced reorganization of lipid 
rafts (Hao and August, 2005), it is tempting to propose that 
  myosin II could play a direct role in recruiting proteins such as 
MHC class II–Ii complexes to these microdomains. As demon-
strated here for myosin II activity, association to lipid rafts was 
indeed suggested to be required for the formation of MHC class II–
peptide complexes (Pierce, 2002; Poloso et al., 2004).
How does myosin II direct the trafﬁ  cking 
of MHC class II–carrying vesicles?
Myosin II could directly transport MHC class II–Ii-containing 
vesicles along actin microfi   laments, thereby directing their 
movement toward the incoming vesicles that carry BCR–Ag 
complexes. Indeed, although myosin II was described as a non-
processive motor protein (i.e., it spends only a small part of its 
ATP hydrolysis cycle bound to actin cables and is therefore 
thought to be unable to transport cargoes on long distances; 
Frank et al., 2004), oligomerized myosin II molecules might be 
able to mediate cargo transport. Alternatively, myosin II could 
act indirectly, possibly by helping to connect the transport of 
MHC II–containing vesicles, which were shown to use micro-
tubules to travel into cells (Wubbolts et al., 1999), to the traffi  ck-
ing of Ag-carrying vesicles, which are most likely associated 
with the actin cortex (Barois et al., 1998; Brown and Song, 
2001). Accordingly, myosin II was shown to coordinate the in-
teractions between actin fi  laments and microtubules and might 
thereby affect the transport of associated organelles (Frank et al., 
2004; Seabra and Coudrier, 2004). In particular, changes in the 
polarization of the microtubule network during cell division 
and in migrating cells were attributed to myosin II activity 
(Rosenblatt et al., 2004; Gomes et al., 2005). Determining 
whether the role of myosin II in MHC class II traffi  cking in 
B lymphocytes is associated with the acquisition of a polarized 
phenotype as in their T counterpart (Jacobelli et al., 2004) 
requires further investigation.
In conclusion, we show here that B cells coordinately 
reorganize their actin cytoskeleton and endocytic pathway in 
  response to an antigenic stimulus, an event that depends on the 
actin-based motor protein myosin II and is absolutely required 
for the processing of BCR-internalized Ag and presentation to 
CD4 T cells. This study provides the fi  rst evidence for the direct 
involvement of a motor protein in the regulation of MHC class 
II traffi  cking in Ag-presenting cells and further suggests the po-
tential implication of myosin II in the traffi  cking of proteins that 
follow similar routes to MHC class II–Ii complexes.
Materials and methods
Mice and cells
I-A
bβ–GFP knockin (referred to as MHC II–GFP), I-A
bβ knockout, and Ii 
knockout mice were previously described (Cosgrove et al., 1991; Bikoff et al., 
1993; Boes et al., 2002). The mouse lymphoma cells A20/DNP express-
ing surface IgM anti-DNP (Watanabe et al., 1988), IIA1.6 (FcγR-defective MYOSIN II–DEPENDENT ANTIGEN PRESENTATION • VASCOTTO ET AL. 1017
variant of A20), and the DO54.8 T cell hybridoma were cultured as re-
ported previously (Lankar et al., 2002). DCs were differentiated from 
mouse bone marrows cultured during 12 d in a granulocyte/macrophage 
colony-stimulating factor–containing medium as described previously (Savina 
et al., 2006).
Antibodies and drugs
The following Abs and inhibitors were used: rat anti–mouse LAMP-1 (BD 
Biosciences), rabbit anti-Igα (Lankar et al., 2002), rabbit anti-DM (pro-
vided by L. Karlsson, Johnson & Johnson Pharmaceutical Research and 
Development, San Diego, CA), rabbit anti–full-length Ii (JV11; Driessen et al., 
1999), rat anti-Ii N terminal (In-1; BD Biosciences), rat anti–I-A
b/d (M5114; 
Bhattacharya et al., 1981), rabbit anti–I-Aβ (Lankar et al., 2002), rabbit 
anti-Rab5 (provided by J.P. Gorvel, Universite de la Mediterranee Parc 
Scientiﬁ  que de Luminy, Marseille, France), goat anti–cathepsin D (Santa 
Cruz Biotechnology, Inc.), mouse anti-RhoA (provided by P. Chavrier, 
Centre National de la Recherche Scientiﬁ  que/Institut Curie, Paris, France), 
rat anti–α-tubulin (Serotec), rabbit anti-MLC and rabbit antiphospho-MLC 
(Thr18/Ser19; both were obtained from Cell Signaling Technology), rabbit 
anti–myosin IIA (Abcam), mouse antiactin (MP Biomedicals), Cychrome-
conjugated anti-B220 (BD Biosciences), phycoerythrin-conjugated anti-IgM 
(BD Biosciences) and phycoerythrin-conjugated anti–I-A
b (BD Biosciences), 
ML-7 and Y27632 (Calbiochem), blebbistatin (Tocris), and LHVS (provided 
by H. Ploegh, Whitehead Institute, Cambridge, MA).
Preparation and stimulation of B cells
A single-cell suspension was generated by the mechanical disruption of 
spleens from 8–12-wk-old mice, and resting mature IgM
+/IgD
+ B cells 
were puriﬁ  ed by negative selection (Miltenyi Biotec). Cell purity was 
80–90% as assessed by ﬂ  ow cytometry using anti-IgM, IgD, and B220 
Abs. For activation, B cells (10
7 cells/ml for biochemical assay and 
5 × 10
5 B cells for immunoﬂ  uorescence) were stimulated using multivalent 
BCR ligands: 10 μg/ml F(ab′)2 goat anti–mouse IgM (Cappel) for primary 
spleen B cells or 10 μg/ml F(ab′)2 goat anti–mouse IgG (MP Biomedicals) 
for IIA1.6 mouse lymphoma cells plus 20 μg/ml F(ab′)2 donkey anti–goat 
(Jackson ImmunoResearch Laboratories). For BCR activation with NP (8-nm 
diameter; Fe2O3; provided by J. Roger, Université Paris 6, Centre National 
de la Recherche Scientiﬁ  que, Paris, France), 10 μg/ml F(ab′)2 goat anti–
mouse IgG or IgM was mixed with 10 μg/ml of recombinant LACK protein 
and a 3.2 vol of NP.
Immunoﬂ  uorescence
B cells plated on poly-L-lysine–coated glass coverslips were ﬁ  xed in 4% PFA 
for 20 min at RT, and PFA was quenched in PBS plus 1 mM glycine for 
10 min. Fixed cells were incubated with Abs in PBS plus 0.2% BSA and 
0.05% saponin. For detection of I-A
d–LACK156–173 complexes, biotinylated 
2C44 and streptavidin-546 (Tyramide Signal Ampliﬁ  cation kit; Invitrogen) 
were used. Immunofluorescence images were acquired on a confocal 
microscope (LSM Axiovert 720; Carl Zeiss MicroImaging, Inc.) with a 
63× 1.4 NA oil immersion objective (Carl Zeiss MicroImaging, Inc.).
Time-lapse analysis
For video microscopy, B cells attached on poly-L-lysine–coated slides were 
incubated in a Ludin chamber at 37°C in the absence or presence of BCR 
multivalent ligands. Fluorescence 3D + time images were acquired every 
2–5 min during  3 h on an inverted fast 4D deconvolution microscope 
(DMIRB2; Leica) using a PL APO HC 1.4 NA oil immersion objective 
(Leica). It was equipped with a cooled interline CCD detector (CoolSNAP 
HQ; Roper) with a pixel size of 6.45 × 6.45 μm, 12 bits of dynamics, 
and a read-out speed of 20 MHz. Z positioning was accomplished by 
a piezoelectric driver (10-nm precision and 40-nm repetitiveness; LVDT; 
Physik Instrument) mounted beneath the objective lens. Illumination was 
provided by a fast wavelength switcher (DG-4; Sutter Instrument Co.). 
We used a 2 × 2 binning and a z distance between planes of 0.3 μm, 
giving a voxel size of 129 × 129 × 300 nm
3, which is compatible 
with the deconvolution process. Images were deconvolved with the 
MetaMorph (Universal Imaging Corp.) point-spread function–based itera-
tive constrained modiﬁ  ed gold algorithm. Films were reconstructed using 
MetaMorph 6.2 software.
Immunoelectron microscopy
1–3 × 10
7 of puriﬁ   ed spleen B cells not pretreated or pretreated with 
  myosin II inhibitors were stimulated with multivalent BCR ligands (see Prep-
aration and stimulation of B cells section) and processed for immunoelectron 
microscopy as previously described (Lankar et al., 2002).
Ag presentation assays
OVA was coupled to DNP (Lankar et al., 2002). Monovalent F(ab) anti–
mouse IgM was prepared by reducing 4 mg F(ab′)2 goat anti–mouse IgM 
with 1 mg Mesna (Pierce Chemical Co.) and was incubated with 8 mg 
  maleimide-activated OVA (Pierce Chemical Co.). Fractions were puriﬁ  ed 
on a Sephadex 75 column (GE Healthcare) and purity tested by immuno-
blotting. Spleen B cells from MHC II–GFP mice (I-A
b haplotype) or A20 
anti-DNP cells (I-A
d haplotype) not pretreated or pretreated with myosin II 
inhibitors were used for stimulation of the B097.10 (I-A
b) or DO54.8 T cell 
hybridomas (I-A
d) as previously described (Lankar et al., 2002).
Immunoprecipitation and pulse-chase analyses
For immunoprecipitations, IIA1.6 cells were not pretreated or pretreated 
with inhibitors for 1 h at 37°C followed by activation with multivalent BCR 
ligands. Alternatively, day 12 bone marrow–derived DCs treated with LPS 
during 30 min were used. Cells were lysed (100 mM Tris, 300 mM NaCl, 
0.5% NP-40, and 5% glycerol plus protease cocktail inhibitors), and 900 μg 
of cell lysates was precleared with rabbit and mouse nonimmune sera 
and/or protein G–coated Sepharose beads. Ii and MHC class II molecules 
were immunoprecipitated using the In-1 rat mAb or M5114 rat mAb, 
respectively. Samples were washed, resuspended in reducing laemmli buffer, 
boiled, and loaded onto a 12% SDS-PAGE gel. Proteins were transferred to 
polyvinylidene diﬂ   uoride membranes (Immobilon-P; Millipore), and mem-
branes were incubated with the appropriate Abs and revealed with ECL (GE 
Healthcare). Alternatively, gels were directly stained with colloidal Coo-
massie blue (Bio-Rad Laboratories). Pulse-chase experiments were performed 
as previously described (Driessen et al., 1999). In brief, spleen B cells 
(20 × 10
6 cells for each time point) were starved in methionine/cysteine-
free RPMI medium for 45 min at 37°C, pulsed with 0.5 mCi [
35S]methionine 
for 30 min at 37°C, further chased for different time points, and lysed, and 
cell extracts were immunoprecipitated using anti–MHC II Ab.
Endosome puriﬁ  cation
50 × 10
6 primary B cells were activated with magnetic NP coupled to 
anti-BCR Abs for 1 h at 37°C, washed with PBS, and resuspended in cold 
homogenization buffer (3 mM imidazol, 8% sucrose, 1 mM DTT, 1 mM 
EDTA, and protease inhibitors). Cells were broken using a cell cracker 
(Lankar et al., 2002), nuclei and intact cells were removed by centrifuga-
tion at 750 g for 10 min, and postnuclear supernatants were collected. 
NP
+ intracellular compartments were semipuriﬁ   ed by incubating post-
nuclear supernatants on a magnet O/N at 4°C. Nonmagnetic and magnetic 
fractions were recovered. Equal protein quantities of the magnetic fraction 
were analyzed by SDS-PAGE.
siRNA transfection
4 × 10
5 IIA1.6 cells were electroporated using nucleofactor R T16 (Amaxa) 
in the presence of 20 nM siRNAs, SMARTpool siRNA, or siGENOME ON-
TARGETplus (#1, 5′-G  G  G  C  U  U  A  U  C  U  A  C  A  C  C  U  A  U  U  U  U  -3′; #2, 5′-A  Y  A  A  G  A-
A  C  C  U  G  C  C  C  A  U  C  U  A  U  U  -3′; #3, 5′-G  C  A  G  A  C  A  A  G  U  A  C  C  U  C  U  A  U  G  U  U  -3′) 
speciﬁ  c for the MYH9 gene or negative control duplex siRNA (5′-U  U  C  U-
C  C  G  A  A  C  G  U  G  U  C  A  C  G  U  T  T  -3′; QIAGEN). Cells were cultured for 96 h at 
37°C and analyzed by immunoblotting or immunoﬂ  uorescence.
Online supplemental material
Videos 1 and 3 show that B cells undergo cell contraction and MHC II–GFP 
clustering upon BCR stimulation. Video 2 shows the behavior of nonstimu-
lated puriﬁ  ed B lymphocytes from MHC II–GFP mice. Videos 4 and 5 show 
that treatment of BCR-stimulated cells with inhibitors of MLC phosphoryla-
tion prevents cell contraction and MHC II–GFP clustering. Fig. S1 A shows 
that full-length Ii is weakly detected in central lysosome clusters, whereas 
H2-DM is enriched in these compartments. Fig. S1 B shows that the pro-
teolysis of Ii is induced upon BCR stimulation. Fig. 1 C shows that there is 
no variation in the steady state levels of MHC class II surface expression at 
various times after BCR stimulation. Fig. S2 shows that BCR capping is not 
modiﬁ  ed in B cells whose myosin II activity is inhibited. Fig. S3 shows a 
characterization of the method used to semipurify the endosomes to which 
BCR–Ag complexes are targeted. Fig. S4 shows that the formation of 
MHC II–peptide complexes from endogenous proteins is not affected by the 
inhibitors of myosin II activity. Fig. S5 shows that Ii and MLC colocalize on ER, 
Golgi, and endosomal membranes. Online supplemental material is avail-
able at http://www.jcb.org/cgi/content/full/jcb.200611147/DC1.
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